Page 52 - 87_01
P. 52
52. Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crus- ANALES
hing: Evaluation of Xtampza® ER and Other ER Opioid Formula- RANF
tions. Clin Drug Investig. 2017 Dec 1;37(12):1117–24.
www.analesranf.com
53. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal Drug De-
livery System: A Review. Vol. 1. 2012. 69. Díaz González LM, Martin Gutiérrez L, Fernández del Pozo M del B.
Epilepsia y Dolor Neuropático. Principios Fisiopatol para la Atención
54. Gomez Ayala M-E. Manipulación de especialidades farmacéuticas. Farm Módulo IV. 2009;18–26.
2007;44–8.
70. Acuña JP. Riesgo de adiccion a analgésicos opioides en el trata-
55. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal pat- miento del dolor crónico no oncológico. Rev Médica Clínica Las Con-
ches: History, development and pharmacology. Br J Pharmacol. des. 2019 Nov 1;30(6):466–79.
2015 Jan 5;172(9):2179–209.
71. Soyka M, Mutschler J. Treatment-refractory substance use disorder:
56. Chandrashekar N, Shobha Rani R. Physicochemical and pharmaco- Focus on alcohol, opioids, and cocaine. Prog Neuro-Psychopharma-
kinetic parameters in drug selection and loading for transdermal cology Biol Psychiatry. 2016 Oct 12;70:148–61.
drug delivery. Indian J Pharm Sci. 2008 Jan 1;70(1):94–6.
72. Conrad C, Bradley HM, Broz D. Community Outbreak of HIV Infec-
57. Delgado-Cortés R, Martínez-Segura RT. Perfil farmacocinético de los tion Linked to Injection Drug Use of Oxymorphone. 2015.
opioides aplicado a la anestesia ambulatoria. Supl 1 Abril-Junio.
2011;34:122–4. 73. Carmen M, Casero V. Deshabituación de opiáceos ( I ). 2011;21(I).
74. Itzoe ML, Guarnieri M. New developments in managing opioid ad-
58 .Kukanich B, Allen P. Comparative pharmacokinetics of intravenous
fentanyl and buprenorphine in healthy Greyhound dogs. diction: Impact of a subdermal buprenorphine implant. Drug Des
Devel Ther. 2017 May 10;11:1429–37.
59. Davis MP, Pasternak G, Behm B. Treating Chronic Pain: An Overview 75. Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic Treatment
of Clinical Studies Centered on the Buprenorphine Option. of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and
Toxicity. J Med Toxicol. 2018 Dec 1;14(4):306–22.
60. Lötsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharma- 76. Pérez-López A, Martín-Sabroso C, Torres-Suárez AI, Aparicio-Blanco
cokinetics of non-intravenous formulations of fentanyl. Clin Phar- J. Timeline of translational formulation technologies for cancer the-
macokinet. 2013 Jan 26;52(1):23–36. rapy: Successes, failures, and lessons learned therefrom. Pharma-
ceutics. 2020 Nov 1;12(11):1–34.
61. Margetts L, Sawyer R. Transdermal drug delivery: Principles and 77. Benéitez MC, Gil-Alegre ME. Opioid Addiction: Social Problems As-
opioid therapy. Contin Educ Anaesthesia, Crit Care Pain. 2007 Oct sociated and Implications of Both Current and Possible Future Tre-
1;7(5):171–6. atments, including Polymeric Therapeutics for Giving Up the Habit
of Opioid Consumption. Biomed Res Int. 2017;2017.
62. Kress HG, Boss H, Delvin T, Lahu G, Lophaven S, Marx M, et al. 78. Ilmo N, Moreno L, Discurso F, Prof C, Alarc FR. Innovaciones farma-
Transdermal fentanyl matrix patches Matrifen® and Durogesic® céuticas para la administración de medicamentos. Real Acad Med
DTrans® are bioequivalent. Eur J Pharm Biopharm. 2010 la Comunidad Val. 2012;46–64.
Jun;75(2):225–31. 79. Goonoo N, Bhaw-Luximon A, Ujoodha R, Jhugroo A, Hulse GK, Jhurry
D. Naltrexone: A review of existing sustained drug delivery systems
63. Hair PI, Keating GM, McKeage K. Transdermal matrix fentanyl mem- and emerging nano-based systems. J Control Release. 2014 Jun
brane patch (Matrifen®): In severe cancer-related chronic pain. 10;183(1):154–66.
Drugs. 2008 Sep 17;68(14):2001–9. 80. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid
addiction in a country in which methadone and buprenorphine are
64. Lane ME. The transdermal delivery of fentanyl. Eur J Pharm Bio- not available. Curr Psychiatry Rep. 2010 Oct;12(5):448–53.
pharm. 2013 Aug 1;84(3):449–55. 81. Kreuter J. Nanoparticles and microparticles for drug and vaccine de-
livery. J Anat. 1996 Dec;189 ( Pt 3(Pt 3):503–5.
65. Likar R. Transdermal buprenorphine in the management of persistent 82. Kjome KL, Gerard Moeller F. Long-acting injectable naltrexone for
pain - Safety aspects. Ther Clin Risk Manag. 2006;2(1):115–25. the management of patients with opioid dependence. Subst Abus
Res Treat. 2011;5(1):1–9.
66. Kress HG. Clinical update on the pharmacology, efficacy and safety 83. Park K, Skidmore S, Hadar J, Garner J, Park H, Otte A, et al. Injec-
of transdermal buprenorphine. Eur J Pain. 2009 Mar;13(3):219– table, long- acting PLGA formulations: Analyzing PLGA and unders-
30. tanding microparticle formation. J Control Release. 2019 Jun
28;304:125–34.
67. Plosker GL, Barkin RL, Breivik H, Gordon A, Hernandez JJ, Hess PE. 84. Jain A, Kunduru KR, Basu A, Mizrahi B, Domb AJ, Khan W. Injectable
Buprenorphine 5, 10 and 20µgh transdermal patch: A review of formulations of poly(lactic acid) and its copolymers in clinical use.
its use in the management of chronic non-malignant pain. Drugs.
2011;71(18):2491–509.
68. Segal H, Salgado B, Mínguez F, Quintero J. Trastornos por consumo
de sustancias y fármacos. Programa Form Médica Contin Acreditado.
2015.
Extended-release delivery systems of opioids:
50 analgesia and dependence
Alexandre Pérez-López, Laura Gómez-Lázaro, et al
An. Real Acad. Farm. Vol. 87. Nº1 (2021) · pp. 35 - 51
